| Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer (NCT05200260) | Shanghai Gynecologic Oncology Group | 2022-07-13 |
| Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) (NCT05329545) | Mersana Therapeutics | 2022-06-23 |
| A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) (NCT05429970) | Memorial Sloan Kettering Cancer Center | 2022-06-17 |
| Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study (NCT05287451) | M.D. Anderson Cancer Center | 2022-05-10 |
| A Study to Investigate LYL797 in Adults With Solid Tumors (NCT05274451) | Lyell Immunopharma, Inc. | 2022-03-29 |
| A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer (NCT05200364) | Sutro Biopharma, Inc. | 2022-03-22 |
| Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer (NCT04575961) | North Eastern German Society of Gynaecological Oncology | 2022-02-22 |
| Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer (NCT05236686) | Shanghai Gynecologic Oncology Group | 2022-02-15 |
| A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer (NCT05198804) | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 2022-01-27 |
| Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) (NCT05092360) | Mural Oncology, Inc | 2022-01-10 |
| A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies (NCT05199272) | 23andMe, Inc. | 2021-12-29 |
| Using Aspirin to Improve Immunological Features of Ovarian Tumors (NCT05080946) | H. Lee Moffitt Cancer Center and Research Institute | 2021-11-02 |
| Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma (NCT05537844) | Liz-Anne Lewsley | 2021-10-27 |
| Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (NCT05041257) | AbbVie | 2021-10-19 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) (NCT05001282) | Elucida Oncology | 2021-09-13 |
| Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC (NCT04983550) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-09-01 |
| A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy (NCT04814875) | THERAPIM PTY LTD | 2021-09-01 |
| A Beta-only IL-2 ImmunoTherapY Study (NCT05086692) | Medicenna Therapeutics, Inc. | 2021-08-27 |
| DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma (NCT03905902) | SOTIO a.s. | 2021-08-01 |
| Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer (NCT04510584) | University Health Network, Toronto | 2021-07-16 |
| A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer (NCT04846842) | Lee's Pharmaceutical Limited | 2021-07-01 |
| Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy (NCT03607955) | Washington University School of Medicine | 2021-06-30 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment (NCT04028479) | Taproot Health | 2021-05-05 |
| Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer (NCT04991051) | AstraZeneca | 2021-05-02 |
| Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients (NCT04375956) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2021-04-26 |
| BrUOG 390: Neoadjuvant Treatment With Talazoparib (NCT04598321) | Brown University | 2021-03-29 |
| CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (NCT04676334) | pharmaand GmbH | 2021-03-22 |
| A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors (NCT04657068) | Artios Pharma Ltd | 2021-01-27 |
| Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS) (NCT04515602) | Shanghai Gynecologic Oncology Group | 2021-01-01 |
| A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab (NCT04590326) | Regeneron Pharmaceuticals | 2020-12-08 |
| Tempus Priority Study: A Pan-tumor Observational Study (NCT05179824) | Tempus AI | 2020-10-19 |
| Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer (NCT04546373) | Grupo Español de Investigación en Cáncer de Ovario | 2020-09-30 |
| A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (NCT04442126) | Numab Therapeutics AG | 2020-08-19 |
| A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies (NCT04440943) | Celldex Therapeutics | 2020-08-04 |
| Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study (NCT04539327) | Grupo Español de Investigación en Cáncer de Ovario | 2020-07-29 |
| A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (NCT04296890) | ImmunoGen, Inc. | 2020-07-23 |
| Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer (NCT05220033) | Rutgers, The State University of New Jersey | 2020-07-14 |
| Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival (NCT04402333) | Royal Surrey County Hospital NHS Foundation Trust | 2020-06-26 |
| Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients (NCT04227522) | North Eastern German Society of Gynaecological Oncology | 2020-06-08 |
| A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy (NCT04229615) | Jiangsu HengRui Medicine Co., Ltd. | 2020-06-02 |
| Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR (NCT04295577) | Royal Marsden NHS Foundation Trust | 2020-02-03 |
| A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression (NCT04209855) | AbbVie | 2019-12-31 |
| High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy (NCT04201561) | Seoul National University Hospital | 2019-12-24 |
| Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy (NCT04204811) | Memorial Sloan Kettering Cancer Center | 2019-12-16 |
| A Trial Evaluating TG4050 in Ovarian Carcinoma. (NCT03839524) | Transgene | 2019-12-09 |
| Genomic BRCA and Extensive ovArian Cancer Testing (NCT04027868) | ARCAGY/ GINECO GROUP | 2019-12-06 |
| Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer) (NCT03891576) | Mario Negri Institute for Pharmacological Research | 2019-11-13 |
| The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer (NCT03921658) | University of Minnesota | 2019-10-22 |
| Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) (NCT03983226) | Shanghai Gynecologic Oncology Group | 2019-10-18 |
| Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery (NCT03373058) | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 2019-10-15 |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) (NCT03824704) | pharmaand GmbH | 2019-08-23 |
| Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer Patients (NCT04537702) | Duke University | 2019-08-08 |
| A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer (NCT04029909) | Lee's Pharmaceutical Limited | 2019-07-11 |
| A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (NCT03849469) | Xencor, Inc. | 2019-05-29 |
| Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer (NCT03430700) | University College, London | 2019-05-16 |
| A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (NCT03872947) | Toray Industries, Inc | 2019-04-26 |
| Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study (NCT06274541) | Cancer Trials Ireland | 2019-03-22 |
| A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) (NCT03657043) | Seagen Inc. | 2019-03-20 |
| HIPEC After Initial CRS in Patients Who Have Received NACT (NCT03540017) | Northwell Health | 2019-03-12 |
| Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube (NCT03771651) | University of Oklahoma | 2019-03-01 |
| Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers (NCT03748186) | Sutro Biopharma, Inc. | 2019-02-01 |
| Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer (NCT03759587) | Takeda | 2018-12-28 |
| Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer (NCT03759600) | Takeda | 2018-12-26 |
| Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer (NCT03693248) | Seoul National University Hospital | 2018-12-19 |
| European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer (NCT03783949) | Universitaire Ziekenhuizen KU Leuven | 2018-11-30 |
| Study of ADCT-301 in Patients With Selected Advanced Solid Tumors (NCT03621982) | ADC Therapeutics S.A. | 2018-11-09 |
| MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03585764) | University of Pennsylvania | 2018-10-24 |
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) (NCT03648489) | Imperial College London | 2018-09-21 |
| Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) (NCT03393884) | Imunon | 2018-09-05 |
| Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy (NCT03593681) | Boston Scientific Corporation | 2018-08-27 |
| A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03635489) | Hoffmann-La Roche | 2018-08-15 |
| BEACON - ABC in Recurrent Platinum Resistant HGSOC (NCT03363867) | Peter MacCallum Cancer Centre, Australia | 2018-07-10 |
| Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer (NCT07648745) | Prof Gordon Jayson | 2018-05-14 |
| PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. (NCT03283943) | British Columbia Cancer Agency | 2018-04-01 |
| Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer (NCT03180177) | Shu-Zhong Cui | 2018-03-01 |
| Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer (NCT03029403) | University Health Network, Toronto | 2018-02-12 |
| Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients (NCT03321188) | Andrea Jewell | 2017-12-15 |
| A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors (NCT03311334) | Sumitomo Pharma America, Inc. | 2017-12-14 |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies (NCT03329950) | Celldex Therapeutics | 2017-12-01 |
| Anti-PD-L1 and SAbR for Ovarian Cancer (NCT03312114) | University of Texas Southwestern Medical Center | 2017-11-09 |
| Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer (NCT03126812) | The Netherlands Cancer Institute | 2017-11-01 |
| The Treatment Preferences of Women Diagnosed With Ovarian Cancer (NCT03367260) | Duke University | 2017-10-19 |
| Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int (NCT03213964) | Masonic Cancer Center, University of Minnesota | 2017-10-19 |
| Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer (NCT03188159) | National University Hospital, Singapore | 2017-07-01 |
| Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer (NCT03056833) | Ronald Buckanovich | 2017-06-10 |
| Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors (NCT03189108) | National Cancer Institute (NCI) | 2017-05-22 |
| CAR T Cells in Mesothelin Expressing Cancers (NCT03054298) | University of Pennsylvania | 2017-04-06 |
| Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab (NCT03093155) | Yale University | 2017-04-03 |
| Homologous Recombination Inquiry Through Ovarian Malignancy Investigations (NCT03159572) | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | 2017-03-28 |
| Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia (NCT04001023) | Turku University Hospital | 2017-03-09 |
| A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03038100) | Hoffmann-La Roche | 2017-03-08 |
| Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer (NCT02948426) | National Cancer Institute (NCI) | 2017-02-08 |
| Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). (NCT02834975) | University of Miami | 2016-12-22 |
| Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer (NCT02915523) | Syndax Pharmaceuticals | 2016-12-19 |
| Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery (NCT02884648) | M.D. Anderson Cancer Center | 2016-11-15 |
| A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib (NCT02873962) | Dana-Farber Cancer Institute | 2016-11-10 |
| Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer (NCT02973750) | H. Lee Moffitt Cancer Center and Research Institute | 2016-10-20 |
| Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer (NCT02865811) | Dana-Farber Cancer Institute | 2016-09-15 |
| HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life (NCT03000192) | University Hospital Southampton NHS Foundation Trust | 2016-08-01 |
| HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma (NCT02487849) | Krankenhaus Barmherzige Schwestern Linz | 2016-08-01 |